Literature DB >> 18977325

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

Andrei V Krivtsov1, Zhaohui Feng, Madeleine E Lemieux, Joerg Faber, Sridhar Vempati, Amit U Sinha, Xiaobo Xia, Jonathan Jesneck, Adrian P Bracken, Lewis B Silverman, Jeffery L Kutok, Andrew L Kung, Scott A Armstrong.   

Abstract

We created a mouse model wherein conditional expression of an Mll-AF4 fusion oncogene induces B precursor acute lymphoblastic (ALL) or acute myeloid leukemias (AML). Gene expression profile analysis of the ALL cells demonstrated significant overlap with human MLL-rearranged ALL. ChIP-chip analysis demonstrated histone H3 lysine 79 (H3K79) methylation profiles that correlated with Mll-AF4-associated gene expression profiles in murine ALLs and in human MLL-rearranged leukemias. Human MLL-rearranged ALLs could be distinguished from other ALLs by their H3K79 profiles, and suppression of the H3K79 methyltransferase DOT1L inhibited expression of critical MLL-AF4 target genes. We thus demonstrate that ectopic H3K79 methylation is a distinguishing feature of murine and human MLL-AF4 ALLs and is important for maintenance of MLL-AF4-driven gene expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977325      PMCID: PMC2591932          DOI: 10.1016/j.ccr.2008.10.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  39 in total

1.  Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity.

Authors:  D P Silver; D M Livingston
Journal:  Mol Cell       Date:  2001-07       Impact factor: 17.970

2.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors:  Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation.

Authors:  Tatsuya Nakamura; Toshiki Mori; Shinichiro Tada; Wladyslaw Krajewski; Tanya Rozovskaia; Richard Wassell; Garrett Dubois; Alexander Mazo; Carlo M Croce; Eli Canaani
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

4.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.

Authors:  T Rozovskaia; E Feinstein; O Mor; R Foa; J Blechman; T Nakamura; C M Croce; G Cimino; E Canaani
Journal:  Oncogene       Date:  2001-02-15       Impact factor: 9.867

5.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

Authors:  Scott A Armstrong; Jane E Staunton; Lewis B Silverman; Rob Pieters; Monique L den Boer; Mark D Minden; Stephen E Sallan; Eric S Lander; Todd R Golub; Stanley J Korsmeyer
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

6.  MLL targets SET domain methyltransferase activity to Hox gene promoters.

Authors:  Thomas A Milne; Scott D Briggs; Hugh W Brock; Mary Ellen Martin; Denise Gibbs; C David Allis; Jay L Hess
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

Review 7.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.

Authors:  P M Ayton; M L Cleary
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

8.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Mary E Ross; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Kevin Girtman; W Kent Williams; Hsi-Che Liu; Rami Mahfouz; Susana C Raimondi; Noel Lenny; Anami Patel; James R Downing
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

9.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.

Authors:  Weili Chen; Quanzhi Li; Wendy A Hudson; Ashish Kumar; Nicole Kirchhof; John H Kersey
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

View more
  247 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 2.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

3.  MLL-AF4 driven leukemogenesis: what are we missing?

Authors:  Ronald W Stam
Journal:  Cell Res       Date:  2012-01-31       Impact factor: 25.617

4.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.

Authors:  Man Mohan; Chengqi Lin; Erin Guest; Ali Shilatifard
Journal:  Nat Rev Cancer       Date:  2010-09-16       Impact factor: 60.716

5.  Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.

Authors:  Hairong Huo; Pellegrino G Magro; E Christy Pietsch; Brijesh B Patel; Kathleen W Scotto
Journal:  Cancer Res       Date:  2010-09-22       Impact factor: 12.701

Review 6.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

7.  IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma.

Authors:  Ying Liu; Wenqing Jiang; Jing Liu; Shimin Zhao; Ji Xiong; Ying Mao; Yin Wang
Journal:  J Neurooncol       Date:  2012-07-08       Impact factor: 4.130

Review 8.  The upstreams and downstreams of H3K79 methylation by DOT1L.

Authors:  Hanneke Vlaming; Fred van Leeuwen
Journal:  Chromosoma       Date:  2016-01-04       Impact factor: 4.316

9.  Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Authors:  Chenxi Shen; Stephanie Y Jo; Chenzhong Liao; Jay L Hess; Zaneta Nikolovska-Coleska
Journal:  J Biol Chem       Date:  2013-09-01       Impact factor: 5.157

10.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Authors:  Eytan M Stein; Guillermo Garcia-Manero; David A Rizzieri; Raoul Tibes; Jesus G Berdeja; Michael R Savona; Mojca Jongen-Lavrenic; Jessica K Altman; Blythe Thomson; Stephen J Blakemore; Scott R Daigle; Nigel J Waters; A Benjamin Suttle; Alicia Clawson; Roy Pollock; Andrei Krivtsov; Scott A Armstrong; Jorge DiMartino; Eric Hedrick; Bob Löwenberg; Martin S Tallman
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.